Altimmune, Inc. ( ALT ) has multiple trials of pemvidutide underway providing it with the ability to differentiate its asset, but it hasn't yet landed a partner or been bought out. In July I rated ALT a hold, noting theScientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, but don't constitute investment advice.Analyst’s Disclosure:I/we have no stock, ...